Spectrum Pharmaceuticals Inc (SPPI)

NASDAQ
2.330
+0.060(+2.64%)
After Hours
2.340
+0.010(+0.429%)
- Real-time Data
  • Volume:
    3,601,901
  • Bid/Ask:
    2.330/2.340
  • Day's Range:
    2.200 - 2.360
  • Type:Equity
  • Market:United States
  • ISIN:US84763A1088
  • CUSIP:00084763A108

SPPI Overview

Prev. Close
2.27
Day's Range
2.2-2.36
Revenue
-
Open
2.27
52 wk Range
2.145-5.24
EPS
-1.29
Volume
3,601,901
Market Cap
371.81M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,743,928
P/E Ratio
-
Beta
2.12
1-Year Change
-44.26%
Shares Outstanding
159,575,898
Next Earnings Date
Nov 11, 2021
What is your sentiment on Spectrum Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Spectrum Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Sell
SummaryStrong BuyStrong BuyStrong BuySellStrong Sell

Spectrum Pharmaceuticals Inc Company Profile

Spectrum Pharmaceuticals Inc Company Profile

Employees
176

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

Read More
  • 4 BIOTECH STOCKS FACING FDA REJECTION!Is it a full stop or a pause to their journey?https://www.reddit.com/r/MicrocapStocksRun/comments/palt5t/4_biotech_stocks_facing_fda_rejection/?utm_source=share&utm_medium=web2x&context=3
    0
    • very good information
      0
      • Website careers section has been updated and includes all the makings of bringing on a sales force. FDA had delayed the approval of Rolantis due to Covid Travel restrictions. Looks like Blackrock has a position as well.
        0
        • SPPI. FDA decision on Rolontis is imminent. Hmmm. Very quiet. 10/23/20 the last and closing price was $3.40. I exited my position in SPPI at $4.40 this summer. Waiting to see how this unfolds.
          0
          • Result?
            0
          • Delayed due to travel issues.
            0
        • 10/24/20: Rolontis Review Decision by FDA. Could be a nice catalyst. We are going to pass on this one, though approval seems likely. Last: $4.07.
          0
          • I suspect investors will receive some sort of notice from the company this week.
            0
        • Looking for another entry on SPPI. Last: $3.93.
          0
          • earnings will be good
            0
            • Sold SPPI at $4.40 on 7/28/20.
              0
              • SPPI. Likely heading higher in back half of 2020.
                0
                • Last price traded: $3.25. SPPI is a buy.
                  0
              • I think should be keep for 2 years.
                0
                • ***I'm stuck at 3.75
                  1
                  • Will soon be there wait for 3 weeks
                    0
                  • Anyone having at higher value will see very fast move upwards. Good opportunity to buy at lower levels
                    0
                • What news we can predict this share will up to $50?
                  0
                  • What news we can predict this share will up to $50?
                    0
                    • Pozi is going to send share price above $50 in next 2 years.
                      0
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.